BioNTech Eyes Morocco for Potential mRNA Vaccine Factory in Africa Expansion

10 August 2021 – bySylvanus@Bladi · 1 min read

BioNTech, a German biotechnology company specializing in the development and manufacture of active immunotherapies in the treatment of serious diseases, is betting on Africa to boost its production. In this sense, it plans to open a factory in one of the following five countries: Morocco, Egypt, South Africa, Tunisia or Senegal.

The German biotech company - which is behind the vaccine developed with Pfizer - has unveiled part of its expansion plan aimed at creating a large factory for the production of innovative medicines in Africa. According to its CEO, Ugur Sahin, the German firm is considering building a factory in Africa and developing a manufacturing network with local partners to transfer its mRNA-based technology - a genetic molecule - to a continent that suffers from a lack of access to vaccines and other vital treatments, reports The Wall Street Journal.

To read:

In its sights are five African countries that have a vaccine industry. These are Morocco, Egypt, South Africa, Tunisia and Senegal. The German firm intends to negotiate the possibilities of opening the factory in one of these countries.

Category: Economy

Keywords:

Germany Tunisia South Africa Health Egypt Africa Industry